chronic hepatitis B. chronic hepatitis C
Conditions
Interventions
Per time point max. 50 ml of peripheral blood and fine needle aspirate biopsies
will be collected.
Sponsors
Stichting Leveronderzoek
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Diagnosed with chronic HCV or chronic HBV * Hepatitis C viral RNA detectable in case of chronic HCV infection or HBsAg positive for over 6 months in case of chronic HBV infection. * Non-cirrhotic compensated liver disease. * Age * 18 years and * 70 years. * Written informed consent.
Exclusion criteria
Exclusion criteria: * Extensive bridging fibrosis indicated by histology (gold standard), imaging, transient elastography or clinical decompensated cirrhosis (Child-Pugh Grade B or C). * Hepatic imaging (ultrasound, CT or MRI) with evidence of hepatocellular carcinoma. * Females who are pregnant or breast-feeding. * History or other evidence of severe illness, malignancy or any other condition which would make the patient, in the opinion of the investigators, unsuitable for the study. * Received prolonged therapy with immunomodulatory agents (e.g. corticosteroids) or biologics (e.g. monoclonal antibody, interferon) within 6 months of screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the functionality of immune cells in the liver and blood in chronic HCV and chronic HBV patients before, and during or after treatment with antiviral treatment, as well as their gene expression profiles. | — |
Countries
Netherlands
Outcome results
None listed